Due to strong sales in all markets, pharmaceutical giant Cipla announced on Tuesday a 17% increase in consolidated net profit to Rs 1,303 crore for the second quarter that ended in September 2024.
In the July–September quarter of the previous fiscal year, the company reported a net profit of Rs 1,115 crore.
According to a regulatory filing by Cipla, its total operating income increased to Rs 7,051 crore in the second quarter from Rs 6,490 crore in the same period last year.
“We achieved a 9% increase in revenue over the previous year in Q2 FY25, with a record-breaking EBITDA margin of 26.7% driven by mix and other operational efficiencies said Umang Vohra, MD and Global CEO of Cipla.
A modified seasonal pattern had an effect on the company’s “One India” business during the quarter. Nonetheless, he noted that important chronic treatments in the branded prescription market kept expanding more quickly than the overall market.
Vohra claims that the company’s consumer health division grew at a strong rate of 21% per year.
“With our concentrated focus on the differentiated portfolio, the US business posted a revenue of USD 237 million. The private sector was the main driver of South Africa’s robust 22% annual growth in local currency, he said.
According to Vohra, a deep market focus strategy helped emerging markets and Europe generate a strong 18% revenue growth.
“In the future, the focus will be on expanding our key markets, strengthening our flagship brands, investing in the pipeline, and concentrating on regulatory resolutions,” he continued.
On the BSE, Cipla shares were up 1.68 percent at Rs 1,478.25 each.